Rapid health technology assessment of lorlatinib in the first-line treatment of anaplastic lymphoma kinase mutation-positive non-small cell lung cancer
Objective To evaluate the safety,efficacy and economy of lorlatinib as the first-line treatment in patients with anaplastic lymphoma kinase(ALK)-positive non-small cell lung cancer(NSCLC)by rapid health technology assessment(rHTA),and to provide evidence for clinical decision makers.Methods Domestic and foreign databases and other major official HTA websites were used,and the related literatures about lorlatinib as first-line treatment for ALK mutation-positive NSCLC patients were included and comprehensively analyzed.Results A total of 9 systematic/meta-analyses and 4 economic studies were included.Efficacy results showed that objective response rate and progression-free survival of lorlatinib were significantly better than other ALK-tyrosine kinase inhibitors and chemicals,but overall survival was not significantly different.Safety results showed that the incidence of adverse events of lorlatinib≥3 was only lower than ceritinib,but controllable.Economic results did not show a significant cost-effectiveness advantage.Conclusion Lorlatinib has efficacy and safety advantages in the first-line treatment of ALK mutation-positive NSCLC patients,but its economic advantages need to be further studied.More safety,effectiveness and economic studies focusing on intuitive comparison and multi-subgroup are necessary.
lorlatinibnon-small cell lung cancerrapid health technology assessment
NETL
NSTL
万方数据
